SMi's 1st Highly Potent Active Pharmaceutical Ingredients 2017
May 22 - 23, 2017 - London UKSMi Group
kwilliams@smi-online.co.uk
Phone:02078276012
In recent years there has been an emerging trend in the global market for Highly Potent Active Pharmaceutical Ingredients, which is largely driven by its major use in oncology for cancer treatment and more often in the form of anti-drug conjugates (ADCs). With this continued development, SMi has been receptive to the steadily increasing market growth and have launched its first Highly Potent Active Pharmaceutical Ingredients conference, set to take place 22nd – 23rd May in London, UK. The conference programme has been produced to enable delegates to gain knowledgeable insight on how to develop highly potent APIs more efficiently, safely and more cost effectively than before. Whether your area of expertise is in process development, scale up, occupational safety or outsourcing, this two day conference is certain to equip you with a wealth of actionable insights. FEATURED SPEAKERS: Alessandro Brigo, Toxicology Project Leader, Pharmaceutical Sciences Andreas Flueckiger, Chief Occupational Health Officer, Roche Gwydion Churchill, Associate Director of Chemistry, Antibiotics Business Unit, AstraZeneca Ildiko Ziegler, Distinguished Validation Expert, Gedeon Richter Hungary Jack Brown, Senior Principal Scientist, Boehringer Ingelheim James Evans, Vice President CMC, NuCana BioMed Jason Hamm, Director of Chemical Development Operations, Bristol-Myers Squibb Richard Denk, Head Sales Containment, SKAN AG CONFERENCE HIGHLIGHTS Address the challenges of working with HPAPIs and approaches to scale-up Discuss strategies for CMO selection and solutions to better communication and transfer Hear about Teva API’s Operational Excellence and QC Lab Transformation Gain insight into the ISPE contamination Manual covering containment issues from the PDE/ OEL to life cycle Learn about Health Hazard Assessment Classifications and the toxicological criteria of potent compounds